Project Grant R01CA292622
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded University of California, San Diego a $699,929 Project Grant on June 20, 2025, under the Cancer Treatment Research program (CFDA 93.395) to enhance immunotherapy response in human papillomavirus negative head and neck squamous cell carcinoma (HPV-HNSCC). The project, which extends through May 31, 2030, focuses on improving dendritic cell (DC) migration to draining sentinel lymph nodes to enhance the efficacy of programmed...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a $988,224 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to advance treatment strategies for head and neck cancer patients with competing health risks through multi-center randomized clinical trials. The four-year award, effective September 1, 2025 through August 31, 2029, supports the principal investigator's clinical research program focused on developing novel alternative therapeutic...
- Federal Project Grant Award Summary The University of California, San Francisco received a $421,685 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to investigate discovery methods for identifying functional immune niches within the tumor microenvironment (TME). Awarded on August 8, 2025, with a completion date of July 31, 2027, this research project will deliver scientific discoveries regarding the cellular and molecular mechanisms that...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $680,598 to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, with an ultimate completion date of August 31, 2030. This five-year research initiative focuses on decoding the Cullin-5 (CUL5) E3 ubiquitin ligase complex to engineer therapeutic T cells with enhanced and durable effector function. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a Project Grant totaling $546,308 under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) effective August 1, 2025, through July 31, 2030. This award funds hypothesis-driven research investigating the functional role of tumor neoantigen-specific T cells in pediatric brain tumors (PBTs). The project will conduct mechanistic studies utilizing the TARGET BRAIN cohort, a prospective...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, San Diego a $534,083 Project Grant effective June 3, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on glucocorticoid signaling mechanisms induced by breast cancer cell-derived extracellular vesicles. The research project, scheduled for completion by May 31, 2030, will investigate how extracellular vesicles produced by breast cancer cells trigger...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395) to support a five-year research initiative extending through July 31, 2030. The project, titled "Aire-Expressing Macrophages as Novel Mediators of Tumor Immune Evasion," focuses on identifying and characterizing tolerogenic macrophage populations...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $618,928 Project Grant to The Regents of the University of California, doing business as University of California, Berkeley, under the Cancer Biology Research program (CFDA 93.396) on June 9, 2025. The award funds a five-year research initiative through May 31, 2030, investigating the immunosuppressive mechanisms of intratumoral regulatory T cells (Tregs) to advance immune-based cancer therapies. The research...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2032. The research project, "Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy," focuses on elucidating how the PD-1 receptor and associated signaling pathways regulate hematopoietic stem and progenitor...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...